Meeting
2023 ASCO Annual Meeting
Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.
Authors
Anna Maloney
Frank H Netter MD School of Medicine, North Haven, CT
Anna Maloney , Anita Giobbie-Hurder , Miklos C. Fogarasi , Patrick Alexander Ott , F. Stephen Hodi , Tamara A. Sussman , Ann W. Silk , Rizwan Haq , David Liu , Megan Leigh Insco , Elizabeth Iannotti Buchbinder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9520)
DOI
10.1200/JCO.2023.41.16_suppl.9520
Abstract #
9520
Poster Bd #
283
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).
First Author: Michael B. Atkins
Poster
2020 ASCO Virtual Scientific Program
Estimating treatment-free survival (TFS) over extended follow-up in patients (pts) with advanced melanoma (MEL) treated with immune-checkpoint inhibitors (ICIs): Five-year follow-up of CheckMate 067.
First Author: Meredith M. Regan
Poster
2020 ASCO Virtual Scientific Program
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers.
First Author: Oliver Klein
Poster
2016 ASCO Annual Meeting
Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).
First Author: Claire Frances Friedman